Summary: As people age, their sleep patterns tend to change, often becoming shorter and more fragmented. According to Alicia Roth, PhD, a sleep psychologist at the Cleveland Clinic, these changes are common but not necessarily permanent. Sleep disturbances, such as reduced deep sleep and frequent nighttime awakenings, are reported by over half of adults aged…
Summary: The American Academy of Sleep Medicine (AASM) has released updated clinical practice guidelines for treating restless legs syndrome (RLS). These new recommendations reflect the latest scientific evidence gathered over the past decade. Key updates include a stronger emphasis on evaluating and treating iron deficiency in patients with RLS and a shift away from long-term…
Summary: Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for TNX-102 SL, a once-daily sublingual tablet designed to improve sleep, reduce pain, and alleviate other symptoms in fibromyalgia patients. The submission is supported by positive results from two phase 3 studies showing reductions in pain and…
Summary: Nxera Pharma, formerly known as Sosei Group, announced that its partner Centessa Pharmaceuticals has initiated a phase 2 trial of ORX750, an oral orexin receptor 2 agonist designed to treat narcolepsy type 1, type 2, and idiopathic hypersomnia. This milestone results in a $3.5 million payment to Nxera, which will be recognized as revenue…
Summary: Axsome Therapeutics reported growth in its sleep medicine portfolio for the third quarter of 2024, driven by increased uptake of its wake-promoting drug, Sunosi. The company also highlighted progress in its late-stage clinical trials for AXS-12 (targeting narcolepsy) and solriamfetol (targeting shift work disorder, ADHD, and other conditions). Axsome plans to release key trial…
Summary: Centessa Pharmaceuticals announced its third-quarter financial results and updates to its development pipeline, including positive interim data from its phase 1 study of ORX750, an orexin receptor 2 agonist aimed at treating narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). Following promising results, Centessa has initiated a phase 2a clinical…
Audio Transcript Tithing — giving ten percent of our income to a church — is a common theme here on the Ask Pastor John podcast. Not so much recently, but in our first decade it did come up a lot, and you can see how in the APJ book, on pages 101–103, if you have…
Summary: A study by researchers at UC San Diego reveals that artificial light disrupts the circadian rhythms of honey bees, reducing their sleep and impairing behaviors crucial for their role as pollinators. The findings highlight the potential threat of light pollution to bee health and, consequently, to the ecosystems and food security that rely on…
Summary: A multidisciplinary study by researchers at the IMT School of Advanced Studies Lucca has found that prolonged mental fatigue can trigger a phenomenon known as “local sleep,” where parts of the brain display sleep-like activity even while awake. This mental exhaustion, linked to the concept of “ego depletion,” reduces self-control, leading to more aggressive…
Summary: Researchers at the University of Sydney have provided objective evidence that cannabinol (CBN), a compound found in aged cannabis, improves sleep quality in rats. For decades, it was believed that aged cannabis induces sleepiness due to CBN buildup, but until now, this claim lacked scientific validation. The study showed that CBN increased both deep…